Premium
Combination of N ‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis
Author(s) -
De Oliveira Claudia Pinto Marques Souza,
Stefano José Tadeu,
De Siqueira Erika Rabelo Forte,
Silva Leonardo Soares,
De Campos Mazo Daniel Ferraz,
Lima Vicência Mara Rodrigues,
Furuya Carlos Kioshi,
Mello Evandro Sobroza,
Souza Fabrício G.,
Rabello Fabíola,
Santos Telma Eugênio,
Nogueira Monize Aydar,
Caldwell Stephen H.,
Alves Venâncio Avancini Ferreira,
Carrilho Flair José
Publication year - 2008
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2007.00215.x
Subject(s) - steatohepatitis , medicine , steatosis , insulin resistance , metformin , gastroenterology , fibrosis , fatty liver , body mass index , liver biopsy , endocrinology , acetylcysteine , insulin , biopsy , biology , biochemistry , disease , antioxidant
Aim: There is no proven medical therapy for the treatment of non‐alcoholic steatohepatitis (NASH). Oxidative stress and insulin resistance are the mechanisms that seem to be mostly involved in its pathogenesis. The aim of our study was to evaluate the efficacy of N ‐acetylcysteine (NAC) in combination with metformin (MTF) in improving the aminotransferases and histological parameters (steatosis, inflammation, hepatocellular ballooning, and fibrosis) after 12 months of treatment. Methods: Twenty consecutive patients (mean age 53 ± 2 years [36–68] and body mass index [BMI] 29 [25–35]) with biopsy‐proven NASH were enrolled in the study. NAC (1.2 g/day) and MTF (850–1000 mg/day) were given orally for 12 months. All patients underwent evaluation of serum aminotransferases, fasting lipid profile and serum glucose, anthropometric parameters, and nutritional status at 0 and 12 months. A low calorie diet was prescribed for all patients. Results: Serum alanine aminotransferase, high‐density lipoprotein, insulin, and glucose concentrations and thehomeostasis model assessment–insulin resistance (HOMA‐IR) index were reduced significantly at the end of study ( P < 0.05). The BMI declined, but without statistical significance. Aspartate aminotransferase, gamma‐glutamyl transferase, alkaline phosphatase, cholesterol, and triglycerides levels were not altered with the treatment. Liver steatosis and fibrosis decreased ( P < 0.05), but no improvement was noted in lobular inflammation or hepatocellular ballooning. The NASH activity score was significantly improved after treatment. Conclusion: Based on the biochemical and histological evidence in this pilot study, NAC in combination with MTF appears to ameliorate several aspects of NASH, including fibrosis. Further studies of this form of combination therapy are warranted to assess its potential efficacy.